[1-hydroxy-2-(4-phenethyl-imidazol-1-yl)-1-phosphono-ethyl]-phosphonic acid | 1233190-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [1-hydroxy-2-(4-phenethyl-imidazol-1-yl)-1-phosphono-ethyl]-phosphonic acid
• 英文别名: [1-Hydroxy-2-[4-(2-phenylethyl)imidazol-1-yl]-1-phosphonoethyl]phosphonic acid
• CAS: 1233190-88-9
• 化学式: C₁₃H₁₈N₂O₇P₂
• 分子量: 376.243
• InChiKey: NPAIQCBKISPQQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
  申请人：Cotesta Simona

  公开号：US20110257131A1

  公开（公告）日：2011-10-20

  (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, wherein one of R 1 and R 2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.

  本发明涉及未替代或替代的苯基-烷基-替代[(咪唑-1-基)-1-羟基-1-膦酸乙基]-膦酸盐，以及其制备方法或过程，其在制药配方中的使用，其在治疗疾病中的使用，其在治疗疾病中的使用方法，包括它们和/或化合物在治疗疾病中的使用的制药配方。这些化合物能够抑制过度或不适当的骨吸收。该化合物的化学式为I，其中R1和R2中的一个如规范中所定义，可以是自由形式，酯形式和/或盐形式。
• [EN] PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS<br/>[FR] COMPOSÉS PHÉNYLALKYL-IMIDAZOLE-BISPHOSPHONATES
  申请人：NOVARTIS AG

  公开号：WO2010076258A1

  公开（公告）日：2010-07-08

  (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1- phosphono-ethyl]-phosρhonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula (I), wherein one of R1 and R2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.

  本文披露了非取代或取代的苯基-烷基取代[(咪唑-1-基)-1-羟基-1-膦酸乙基]-膦酸盐化合物的制备方法或工艺，它们在制造药物配方中的使用，它们在治疗疾病中的使用，使用它们治疗疾病的方法，包括它们和/或化合物在治疗疾病中的使用的药物配方。这些化合物能够抑制过度或不适当的骨吸收。化合物的公式为(I)，其中R1和R2中的一个如规范所定义，可以是自由形式、酯形式和/或盐形式。